Chandrav De

Chandrav completed his bachelor’s and master’s degrees in Microbiology from the University of Calcutta in India. During his studies and working in an infectious disease lab in India, he characterized the spectrum of opportunistic infections in AIDS patients in Eastern India.

Chandrav moved to the United States to pursue his Ph.D. in Microbiology and Immunology at SUNY Upstate Medical University in Syracuse, New York. During graduate school, he characterized and identified the mechanism of action of a new L-nucleoside anti-viral compound.

After graduate school, Chandrav joined the Institute of Global Health and Infectious Diseases at the University of North Carolina (UNC) at Chapel Hill to study the role of innate and adaptive immune responses against viral diseases. His research led to the development of novel pre-clinical small animal models to study human tropic viral pathogenesis, the characterization of immune responses and the pre-clinical evaluation of novel anti-viral strategies. After a fruitful training at UNC Chapel Hill, Chandrav joined a cancer immunotherapy lab at UNC Charlotte to develop and characterize novel immunotherapies against solid tumors.

In his pursuit to expand his scientific horizons, Chandrav decided to join Dewpoint Therapeutics to understand the science of condensate biology and how it can be used for developing novel targets against various diseases.